|
[1]
|
Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier. 2008;p. 638. |
|
[2]
|
Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013−2018. http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/EndGameStratPlan_20130208_ENG.pdf. [2013-4-10].http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/EndGameStratPlan_20130208_ENG.pdf |
|
[3]
|
Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol Rec 2014;89(9):73 − 92. https://pubmed.ncbi.nlm.nih.gov/24707513/.https://pubmed.ncbi.nlm.nih.gov/24707513/ |
|
[4]
|
Progress towards global poliomyelitis eradication: preparation for the oral poliovirus vaccine cessation era. Wkly Epidemiol Rec 2004;79(39):349 − 55. https://pubmed.ncbi.nlm.nih.gov/15571172/.https://pubmed.ncbi.nlm.nih.gov/15571172/ |
|
[5]
|
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010;85(23):213 − 28. https://pubmed.ncbi.nlm.nih.gov/20545051/.https://pubmed.ncbi.nlm.nih.gov/20545051/ |
|
[6]
|
World Health Organization. Report of the interim meeting of the Technical Consultative Group (TCG) on the global eradication of poliomyelitis. Geneva: World Health Organization, 2003. http://apps.who.int/iris/bitstream/10665/67859/1/WHO_VB_03.04_eng.pdf.http://apps.who.int/iris/bitstream/10665/67859/1/WHO_VB_03.04_eng.pdf |
|
[7]
|
Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985−91. BMJ 1992;305(6845):79 − 82. http://dx.doi.org/10.1136/bmj.305.6845.79CrossRef
|
|
[8]
|
Andrus JK, Strebel PM, de Quadros CA, Olivé JM. Risk of vaccine-associated paralytic poliomyelitis in latin America, 1989−91. Bull World Health Organ 1995;73(1):33 − 40. https://pubmed.ncbi.nlm.nih.gov/7704923/.https://pubmed.ncbi.nlm.nih.gov/7704923/ |
|
[9]
|
Teixeira-Rocha ES, Carmo EH, Tavares-Neto J. The occurrence of vaccine-associated paralytic poliomyelitis in Brazil, 1995 to 2001. Rev Panam Salud Publica 2005;18(1):21 − 4. https://scielosp.org/article/rpsp/2005.v18n1/21-24/pt/.https://scielosp.org/article/rpsp/2005.v18n1/21-24/pt/ |
|
[10]
|
Hao LX, Toyokawa S, Kobayashi Y. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis 2008;61(2):100 − 3. https://pubmed.ncbi.nlm.nih.gov/18362395/.https://pubmed.ncbi.nlm.nih.gov/18362395/ |
|
[11]
|
Kohler KA, Banerjee K, Gary Hlady W, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 2002;80(3):210 − 6. https://pubmed.ncbi.nlm.nih.gov/11984607/.https://pubmed.ncbi.nlm.nih.gov/11984607/ |
|
[12]
|
Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004;292(14):1696 − 701. http://dx.doi.org/10.1001/jama.292.14.1696CrossRef
|
|
[13]
|
Landaverde JM, Trumbo SP, Danovaro-Holliday MC, Cochi SE, Gandhi R, Ruiz-Matus C. Vaccine-associated paralytic poliomyelitis in the postelimination era in Latin America and the Caribbean, 1992-2011. J Infect Dis 2014;209(9):1393 − 402. http://dx.doi.org/10.1093/infdis/jit602CrossRef
|
|
[14]
|
Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014;210(Suppl 1):S380 − 9. http://dx.doi.org/10.1093/infdis/jiu184CrossRef
|